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Abstract
Background: Inflammatory bowel disease (IBD) is characterized by chronic inflammation of the gastrointestinal
tract that is associated with changes in the gut microbiome. Here, we sought to identify strain-specific functional
correlates with IBD outcomes.
Methods: We performed metagenomic sequencing of monthly stool samples from 20 IBD patients and 12 controls
(266 total samples). These were taxonomically profiled with MetaPhlAn2 and functionally profiled using HUMAnN2.
Differentially abundant species were identified using MaAsLin and strain-specific pangenome haplotypes were
analyzed using PanPhlAn.
Results: We found a significantly higher abundance in patients of facultative anaerobes that can tolerate the increased
oxidative stress of the IBD gut. We also detected dramatic, yet transient, blooms of Ruminococcus gnavus in IBD
patients, often co-occurring with increased disease activity. We identified two distinct clades of R. gnavus strains,
one of which is enriched in IBD patients. To study functional differences between these two clades, we augmented the
R. gnavus pangenome by sequencing nine isolates from IBD patients. We identified 199 IBD-specific, strain-specific genes
involved in oxidative stress responses, adhesion, iron-acquisition, and mucus utilization, potentially conferring an adaptive
advantage for this R. gnavus clade in the IBD gut.
Conclusions: This study adds further evidence to the hypothesis that increased oxidative stress may be a major factor
shaping the dysbiosis of the microbiome observed in IBD and suggests that R. gnavus may be an important member of
the altered gut community in IBD.
Background
Inflammatory bowel disease (IBD) is a chronic inflam-
matory disease of gastrointestinal tract with two main
clinical manifestations: Crohn’s disease (CD) and ulcera-
tive colitis (UC). The pathogenesis of IBD in genetically
susceptible individuals likely involves an overactive immune
response to the gut microbiome [1]. Changes in the intestinal
microenvironment may contribute to the altered gut micro-
bial community composition in IBD. The inflammation of
IBD is associated with increased generation of reactive
oxygen species (ROS) and reactive nitrogen species (RNS),
causing oxidative stress for both host cells and the gut
microbiome [2–4]. Additionally, the gut microbiome in
IBD shows dysbiosis characterized by increased abundance
of functional pathways involved in the microbial response
to oxidative stress [5]. However, the species and/or strains
of microbes that contribute to this functionality remain
unclear.
The increased availability of whole metagenome
sequencing, as opposed to 16S rRNA gene sequencing,
has provided the opportunity to study the taxonomic
composition of microbiomes at unprecedented resolution,
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allowing strain-level and functional profiling. In addition,
several computational tools for metagenomic sequencing
data have recently enabled high-resolution study of specific
strain variants within abundant species [6, 7]. It is increas-
ingly clear that strain variability can result in important
physiological and functional differences in how microbes
interact with the host [8]. For example, different strains of
the same species can provoke different host immune
responses [8], and in the context of IBD, analysis of Escheri-
chia coli showed a specific enrichment of adherent invasive
E. coli (AIEC) strains in IBD vs. healthy individuals [9].
IBD is characterized by relapsing inflammation followed
by periods of remission, highlighting the importance of
tracking patients and their microbiome over time. Because
the symptoms of IBD vary temporally, it is important to
collect multiple samples from each patient to understand
the changing landscape of the IBD gut microbiome.
Furthermore, longitudinal studies of healthy individuals
have revealed large inter-subject variations within the gut
microbiome [10–12], suggesting the importance of un-
derstanding IBD disease-specific effects across multiple
individuals. One notable study performed metagenomic
sequencing on longitudinal IBD samples [13]. With
recently developed tools, it is now possible to analyze
large-scale, longitudinal, metagenomic cohorts to study
the IBD gut microbiome at the strain level.
In this study, we aim to address two outstanding ques-
tions in IBD: 1) How does oxidative stress in IBD shape
the composition of the gut microbiome at the species and
strain levels? 2) Do IBD-associated strains have specific
genomic adaptations that increase their fitness in the IBD
gut? We used metagenomic sequencing of a longitudinal
cohort to analyze functionally binned microbial species by
their ability to tolerate oxidative stress, and we found
increased abundance of facultative anaerobe species in the
IBD gut. We detected dramatic, transient blooms in the
relative abundance of Ruminococcus gnavus in IBD, often
corresponding with increased disease activity. We further
experimentally characterized aerotolerance of R. gnavus
and identified an R. gnavus clade that is enriched in IBD
patients and has a distinct functional repertoire including
genes exclusively present in this clade. These genes often
involve functions that may improve colonization of the
IBD gut, including oxidative stress responses, adhesion,
iron acquisition, and mucus utilization. This study high-
lights the importance of strain-level analysis to reveal
IBD-specific taxonomic features and their functionality.
Methods
Sample collection
Samples from the PRISM study, collected at Massachusetts
General Hospital
A subset of the PRISM cohort was selected for longitudinal
analysis. A total of 15 IBD cases (nine CD, five UC, one
indeterminate colitis) were enrolled in the longitudinal
stool study (LSS). Three participants with gastrointestinal
symptoms that tested negative for IBD were included as a
control population. Enrollment in the study did not affect
treatment. Stool samples were collected monthly, for up
to 12 months. The first stool sample was taken after
treatment had begun. Comprehensive clinical data for
each of the participants was collected at each visit. At
each collection, a subset of participants were interviewed to
determine their disease activity index, the Harvey-Bradshaw
index for CD participants and the simple clinical colitis
activity index (SCCAI) for UC participants (Additional file 1:
Table S1).
Samples collected at Emory University
To increase the number of participants in our analysis, a
subset of the pediatric cohort STiNKi was selected for
whole metagenome sequencing including five individuals
with UC and nine healthy controls. All selected UC cases
were categorized as non-responders to treatment [14].
Stool samples were collected approximately monthly for
up to 10 months. The first sample from participants in the
STiNKi cohort is before treatment started, and subsequent
samples are after treatment started. Stool collection and
DNA extraction methods are detailed in Shaw et al. [14].
DNA and RNA isolation
Samples from the PRISM study, collected at Massachusetts
General Hospital
DNA was extracted from stool using the QIAGEN AllPrep
RNA/DNA Mini kit with an enzymatic and mechanical
lysis step. Lysozyme and proteinase K were added to frozen
stool as described in the QIAGEN RNAprotect Bacteria
Reagent handbook with a 10-min incubation at room
temperature while vortexing every 2 min. Samples were
resuspended in RLT buffer and 0.1 mm glass beads were
added for mechanical lysis with bead beating on a Mini
Bead beater-8 from BioSpec products on the homogenize
setting for 3 min. Debris was removed by two sequential
centrifugation steps at maximum speed for 5 min.
Supernatant was transferred to a QIAshredder spin column
and homogenized lysate was added to the AllPrep spin
column for DNA and RNA extraction using the QIAGEN
protocol.
Samples collected at Emory University
Total nucleic acid was extracted via the Chemagic MSM I
with the Chemagic DNA Blood Kit-96 from Perkin Elmer.
This kit combines chemical and mechanical lysis with
magnetic bead-based purification. Prior to extraction on
the MSM-I, TE buffer, lysozyme, Proteinase K, and RLT
buffer with beta-mercaptoethanol were added to each
stool sample. The stool lysate solution was vortexed to
mix. Samples were then placed on the MSM I unit. The
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following steps were automated on the MSM I. M-PVA
Magnetic Beads were added to the stool lysate solution and
vortexed to mix. The bead-bound total nucleic acid was
then removed from solution via a 96-rod magnetic head
and washed in three ethanol-based wash buffers. The beads
were then washed in a final water wash buffer. Finally, the
beads were dipped in elution buffer to re-suspend the
DNA sample in solution. The beads were then removed
from solution, leaving purified TNA eluate. The eluate was
then split into two equal volumes, one meant for DNA and
the other for RNA. SUPERase-IN solution was added to
the DNA samples, the reaction was cleaned up using
AMPure XP SPRI beads. DNase was added to the RNA
samples, and the reaction was cleaned up using AMPure
XP SPRI beads. DNA samples were quantified using a
fluorescence-based PicoGreen assay. RNA samples were
quantified using a fluorescence-based RiboGreen assay.
RNA quality was assessed via smear analysis on the
Caliper LabChip GX.
Fecal calprotectin quantification
Fecal calprotectin (FCP) was assayed for each stool sample
with the Eagle Biosciences Calprotectin Enzyme-Linked
Immunoabsorbent Assay (ELISA) kit using standard
protocols.
Validation cohorts
Data from an IBD study by Lewis et al. [13] was down-
loaded from the NCBI SRA for use as an IBD validation
cohort. Eighty samples from the Human Microbiome Pro-
ject (HMP) were used as a healthy validation cohort [15].
Analysis of whole metagenome sequencing data
The whole metagenome data were trimmed and human
reads were filtered using KneadData using the default
parameters. Community composition was calculated with
MetaPhlan2 [16] using the default settings. Functional and
pathway composition was calculated with HUMANn2 [17]
using the UniRef90 database with default settings. Differ-
entially abundant species were identified using MaAsLin.
Strain-level analysis was performed using StrainPhlAn
[7] with the default parameters and PanPhlAn [6] with
(–min_coverage 1 –left_max 1.70 –right_min 0.30).
While strain-level profiling using StrainPhlAn was carried
out for 72 species of the gut microbiome with sufficient
coverage, R. gnavus was the only species detected to have
an IBD-specific strain.
The phylogenetic tree of R. gnavus strains was calcu-
lated from the R. gnavus marker gene SNP profiles, as
produced by StrainPhlAn [7]. We used the phangorn R
package to (1) calculate the distance between all profiles
(using the Jukes and Cantor model); (2) construct the
tree using a hierarchical clustering method (UPGMA
(Unweighted Pair Group Method with Arithmetic Mean));
and (3) calculate the bootstrapped phylogeny using the
bootstrap.pml function. To find species with decreased
abundance during blooms of R. gnavus, we divided the
samples into two groups: those with ≥ 10% relative abun-
dance of R. gnavus, and those with < 10%relative abundance
of R. gnavus. Then, we used MaAsLin to find differentially
abundant species between the two groups.
Binning by aerotolerance methods
Based on the relative abundance output of MetaPhlAn2
[16], we binned the species of the gut microbiome based
on aerotolerance. We binned into two groups, anaerobes
and facultative anaerobes. To define differential bins of
aerotolerance, we started with the list assembled by
[18] and expanded for abundant genera in our samples
(Additional file 2: Table S2). Differences in the abundance
of facultative anaerobes was calculated in R using nested
ANOVA.
Survival in aerobic conditions
E. coli Sakai (RIMD 0509952), R. gnavus (ATCC 29149),
and Eubacterium elegans (ATCC 3376) were grown
anaerobically at 37 °C in brain heart infusion media (BD)
supplemented with 1% BBL vitamin K1-hemin solution
(BD), 1% trace minerals solution (ATCC), 1% trace vita-
mins solution (ATCC), 5% fetal bovine serum (Hyclone),
1 g/L cellubiose, 1 g/L maltose, 1 g/L fructose, and 0.5 g/L
cysteine. Confluent cultures diluted into 1 mL of fresh
media and incubated anaerobically for 3 h at 37 °C, at
which point dilutions of the cultures were plated to deter-
mine colony forming units (CFU). The cultures were then
moved to an aerobic tissue culture rotator where they were
incubated at 37 °C with loosened lids. Samples were taken
anaerobically to determine CFUs after 1- and 3-h aerobic
incubation.
Sequencing of 11 R. gnavus strains
DNA libraries were constructed from 11 R. gnavus
strains using a previously described automated micro-
fluidic sample preparation device [19]. This device was
used to minimize reagent cost and hands-on time. The
device takes cells as input (<2 uL aliquots required) and
subsequently performs enzymatic cell lysis, genomic DNA
purification, tagmentation to construct DNA sequencing
libraries, library cleanup, size selection, and elution. All
mixing and elution steps are performed in the device,
using valves in the two-layer microfluidic architecture.
DNA capture and cleanup are achieved using solid phase
reversible immobilization (SPRI) beads inside the device.
The tagmentation reaction was performed following
the Illumina Nextera protocol using the Tagment DNA
Enzyme (Illumina), as described in Kim et al. [19].
The sequencing libraries from the device were barcoded
with dual barcoding primers from the Broad Institute
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(Broad Genomics Platform). The entire volume of DNA
library eluted from the device (8 μL) was mixed with
10 μL of NEBNext High Fidelity 2X PCR MasterMix, 1 μL
forward primer, and 1 μL reverse primer. We performed
PCR barcoding and amplification with the following
protocol: 72 °C for 3 min; 98 °C for 30 s; 17 cycles of
98 °C for 10 s, 60 °C for 30 s, 72 °C for 30 s; and 72 °C
for 5 minutes. The barcoded DNA was cleaned up with
SPRI purification.
Barcoded libraries were quantified with Quant-iT
(ThermoFisher) and pooled at equal concentrations.
DNA sequencing was performed on Illlumina MiSeq
(2 × 150 cycle runs).
Assembly and annotation of new R. gnavus genomes
Raw MiSeq data were trimmed with Trimmomatic using
the parameters: LEADING:3 TRAILING:3 SLIDING-
WINDOW:4:15 MINLEN:80 Then, the data were
assembled with SPAdes with the default parameters and
annotated with Prodigal using the default parameters.
Generation of a custom pangenome database for R. gnavus
Only three R. gnavus genomes were integrated into the
default pangenome database supplied with PanPhlAn [6].
To create a more comprehensive pangenome database, we
used an additional three reference genomes available from
the NCBI as well as 11 newly assembled R. gnavus isolate
genomes.
Identification of IBD-specific genes
Using the coverage output for each gene in the pangenome
from PanPhlAn [6], we identified IBD-specific genes,
which are genes present in multiple IBD samples with
greater than 10× cumulative coverage across all samples,
that are undetectable in all controls from both the LSS
and validation cohorts, including 80 stool metagenomes
from the HMP. We used extremely stringent criteria for
the identification of IBD-specific genes. Instead of only
using samples where the coverage of R. gnavus is greater
than 1×, as is the default for PanPhlAn, we used all
samples. If a gene was present, even at very low coverage
in a healthy sample, it was not considered to be an IBD-
specific gene.
Results
In order to determine how oxidative stress in IBD shapes
the composition of the gut microbiome over time, we
generated metagenomic sequencing data for a longitudinal
stool study (LSS) including adult subjects from the PRISM
(Prospective Registry in IBD Study at Massachusetts
General Hospital) cohort as well as a pediatric cohort
from Emory University which previously has been analyzed
using 16S rRNA gene sequencing [14]. In total, the LSS
cohort includes 266 samples from 20 IBD patients and 12
controls. Stool samples were collected monthly, for up to
12 months per patient, where the first stool sample was
taken after treatment had begun. To validate and support
our findings with other IBD cohorts, we additionally
analyzed 331 metagenomics samples from Lewis et al. [13],
a longitudinal microbiome study of CD patients with four
time points, 0, 1, 4, and 8 weeks. To increase our analysis
of healthy controls, we also examined 80 metagenomic
samples from the Human Microbiome Project (HMP) [15].
An overview of these subjects’ phylum-level gut microbiome
profiles stratified by genus gut microbial profiles shows the
trajectory over time (Fig. 1a).
Aerotolerance signature found in IBD differentially
abundant species
To determine how the increased oxidative stress of the
IBD gut shapes the composition of the gut microbiome,
we first needed to bin the species of the gut microbiome
by their ability to respond to oxidative stress (rather than
by their taxonomic classification). Based on literature
review (“Methods”), we manually binned species into two
categories: i) oxygen-utilizing organisms (also known as
facultative anaerobes, which can grow with or without
oxygen); and ii) organisms that cannot use oxygen as a ter-
minal electron acceptor (namely, aerotolerant and obligate
anaerobes, which are both unable to grow in oxygen;
however, unlike obligate anaerobes, aerotolerant bac-
teria are not rapidly poisoned by atmospheric oxygen)
(Additional file 2: Table S2).
We found a consistent signal of increased facultative
anaerobe abundance in IBD patients across both the LSS
and the Lewis et al. cohorts (p value = 0.0478 and 0.005,
respectively; Fig. 1b). IBD patients from the LSS and
Lewis et al. cohorts showed mean relative abundances of
facultative anaerobes of 9.73 and 19.48%, respectively. In
contrast, control individuals from the HMP, LSS, and
Lewis et al. cohorts showed mean relative abundances of
facultative anaerobes of 1.36, 1.78, and 1.45%, respectively
(Fig. 1b). Thus, IBD patients across three different clinical
centers all showed a markedly increased abundance of fac-
ultative anaerobes. These facultative anaerobe species may
have a fitness advantage compared to the other anaerobic
commensals of the healthy gut, because they may be able
to tolerate the increased oxidative stress of the IBD gut.
In addition to the overall class of facultative anaerobes that
were enriched in IBD patients, we identified individual taxa
that were significantly enriched or depleted (“Methods”).
This detected 15 enriched and nine depleted species
(q < 0.25, Additional file 3: Table S3). These agreed
broadly with previous studies of gut microbial profiles in
IBD, including depletion of Clostridales in Bacteroidales
species (e.g., Faecalibacterium prausnitzii) as also
observed in, e.g., Lewis et al. [13]. Previous studies have
also observed increases of E. coli, Klebsiella pneumoniae,
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and Veillonella species in IBD patients [13]. While we
observed blooms of these species in a few patients with
IBD trending in the same direction, these did not reach
statistical significance in our cohort and test. Other dif-
ferences included a lack of Bifidobacterium species in
our study; both of these discrepancies with respect to
the Gevers et al. [20] cohort may be due to a combination
of age (20–66 years here, 3–17 years in Gevers et al.) and
sample type (stool vs. predominantly biopsy) differences
between the studies.
Of the nine-identified species that showed consistent
differences in abundance between IBD patients and con-
trols in both the LSS and the Lewis et al. cohorts, eight
could be explained by their tolerance to oxidative stress.
Two facultative anaerobes showed increased abundance
in IBD patients (Streptococcus salivarius and Streptococcus
parasanguinis), whereas six anaerobes showed decreased
abundance in the IBD samples (including Blautia obeum
and Alistipes putredinis; Additional file 3: Table S3). These
findings are consistent with previous observations of
enriched abundance of proteobacteria species in the IBD
gut, as these species are facultative anaerobes. The one
remaining differentially abundant species, which was not
apparently explained by its tolerance to oxidative stress,
was R. gnavus. Despite being classified as an anaerobe,
R. gnavus was more abundant in IBD patients. Indeed,
of all bacterial species, R. gnavus showed the greatest
increased abundance in IBD patients compared to
controls in both the LSS and Lewis et al. cohorts
(Additional file 3: Table S3).
R. gnavus transiently dominates the gut microbiome of
IBD patients
We identified R. gnavus blooms in 8/20 and 26/86 individ-
uals from the LSS and Lewis et al. cohorts, respectively
(defining a bloom as greater than 5% relative abundance). R.
gnavus clearly stands out among all differentially abundant
species as dominating the gut microbiome of IBD patients.
The maximum relative abundance of R. gnavus in IBD
patients from the LSS and Lewis et al. cohorts was 41.6 and
69.5%, respectively, whereas the maximum relative abun-
dance was only 2.44% across all controls from these cohorts
and only 1.06% in healthy HMP participants (Fig. 2a).
Interestingly, the increased abundances of R. gnavus in
IBD patients were transient—typically spanning only one
or two time points (Fig. 2b). These transient increases
were detected in patients from the three different clinical
centers and are therefore unlikely to be a geographical
anomaly. In subject 8808 from the LSS cohort, a
bloom in R. gnavus corresponded with a peak in the
Harvey-Bradshaw Index (HBI), a clinical measure of
disease activity, but the overall correlation between HBI
did not reach significance (Fig. 2c). Blooms of R. gnavus
also corresponded with significant decreases of previously
identified IBD-depleted species, including F. prausnitzii
(q-value = 3.04e-10; full list in Additional file 4: Table S4).
The longitudinal nature of our cohorts was critical for this
discovery, as it is impossible to identify transient blooms
from cross-sectional data.
Aerotolerance classification of R. gnavus
The increased abundance of R. gnavus was surprising in
light of its classification as an obligate anaerobe because
the other species increased in the IBD gut were facultative
anaerobes. Therefore, we sought to test the bacteria’s
ability to survive or grow in the presence of oxygen in
the lab. We tested the aerotolerance of R. gnavus ATCC
29149 (isolated from healthy human stool [21]) relative
to a facultative anaerobe (E. coli) and a strict anaerobe
that was considerably less abundant in IBD (E. elegans).
We found that while it is unable to grow in the presence
of oxygen, R. gnavus retained 106 viable cells after 1 h of
atmospheric oxygen exposure and 104 viable cells after
3 h in the presence of oxygen (see “Methods”). In
contrast, E. elegans was unable to tolerate atmospheric
oxygen at all, falling below our limit of detection even
after only 1 h of exposure. The increased tolerance of
R. gnavus to atmospheric oxygen may contribute to its
blooms in the IBD gut (Fig. 2d).
R. gnavus strains represent two phylogenetically distinct
clades
The presence of R. gnavus in healthy and control samples,
albeit in a much lower abundance, made us consider
whether it had different functionality when present in high
abundance in IBD patients. Sequencing many strains of
bacteria from the same species has revealed that different
strains can have dramatically different functionality due to
a large number of highly variable accessory genes.
First, we examined whether we could detect different
strains of R. gnavus in our samples. One way to identify
multiple strains would be to take a closer look at genes
(See figure on previous page.)
Fig. 1 Dynamics of longitudinal microbial composition and facultative anaerobic microbial profiles in inflammatory bowel disease. a Individual
microbial trajectories of 20 inflammatory bowel disease (IBD) patients and 11 control individuals with sufficient longitudinal data over time, from
the current study (Massachusetts General Hospital, p-identifiers) and (Emory University, S-identifiers). Each subject exhibits an individualized microbiome
signature. Each phylum has an overall color while genera are represented as different shades of the overall color. b Maximal relative abundances of
facultative anaerobes across all subjects in the LSS (n = 266), Lewis et al. (n = 368) [13], and HMP (n = 80) [15] cohorts. Overall, facultative anaerobes are
significantly higher in IBD patients compared to controls (nested ANOVA LSS p = 0.0478, Lewis et al. p = 0.005)
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that are annotated as belonging only to R. gnavus genome
(denoted “marker genes”). Nucleotide variations in reads
mapping to such marker genes would suggest the
presence of multiple strains of this species. Indeed,
using single nucleotide polymorphism (SNP) profiles of
R. gnavus marker genes, we identified two prominent
clades of R. gnavus strains, which we named clade 1
and clade 2 (Fig. 3).
Most commonly, strains from the same individual belong
to the same clade, with several exceptions. One notable
case is patient 8808, whose gut microbiome underwent a
shift between months 10 and 11, coinciding with an in-
crease in the Harvey-Bradshaw Index (HBI) of disease.
The higher abundance of R. gnavus found at month 11
(41.6% relative abundance) is not merely an expansion
of the previous strain, belonging to clade 1, but rather a
bloom of R. gnavus clade 2 (Figs. 2c and 3).
Second, we wanted to examine the functional differences
between these two clades. We used the collection of gene
families from all sequenced reference R. gnavus genomes
(denoted as the R. gnavus pangenome) to search for genes
that are differentially present in the two clades, suggesting
b
a c
d
Fig. 2 R. gnavus transiently dominates the gut microbiome in IBD. a The maximum relative abundance of R. gnavus across samples (time courses)
is shown for all subjects in the LSS (n = 266), Lewis et al. (n = 368), and HMP (n = 80) cohorts. While the abundance of most anaerobes are lower
in IBD patients, the abundance of R. gnavus is significantly higher in IBD patients compared to controls. b Relative abundance of R. gnavus over
time for IBD patients in the LSS cohort. The abundance of R. gnavus is not constantly high, but rather has transient increases in the IBD gut. c A
principle coordinate analysis (PCoA) of the Bray-Curtis distance of species-level microbial communities of LSS IBD patient p8808 over 9 months.
The dominant R. gnavus strain in months 4–10 and month 12 is R. gnavus clade 1, while in month 11 the dominant strain of R. gnavus is R. gnavus
clade 2 (Fig. 3). Inset shows the Harvey-Bradshaw Index (HBI) score, a clinical indication of active disease and inflammation, for this patient over time.
The dramatic, transient increased abundances of R. gnavus in month 11 corresponds to an increase in HBI values (i.e., disease activity). d Colony
forming units of R. gnavus, Eubacterium elegans, and E. coli at 0, 1, and 3 h post-transfer to atmospheric oxygen conditions (see “Methods”). Error bars
represent standard deviation. Dotted line signifies limit of detection. No colonies were detected for the obligate anaerobe E. elegans at the 1- and 3-h
time points. As expected, E. coli showed growth during oxygen exposure, and interestingly, despite being classified as an obligate anaerobe, R. gnavus was
able to tolerate atmospheric oxygen for several hours, which may partially explain its increased abundance in the increased oxidative stress of the IBD gut
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different functional potential. To perform this analysis, we
used the PanPhlAn tool [6]. Because its pre-computed
pangenome database for R. gnavus lacked sufficient repre-
sentatives from clade 2, we increased our pangenome
coverage for clade 2 strains by sequencing and assembling
genomes of 11 additional isolates of R. gnavus from IBD
patients and infants (in addition to the currently existing
six reference genomes; Additional file 5: Table S5). The
new R. gnavus pangenome contained 11,933 genes with
an average of 3117 genes per genome. Only 1178 genes
were found in all 17 R. gnavus genomes, indicating that
74% of the R. gnavus genome is variable between strains.
The size of the variable genome ranges from 1708 to
2473 genes.
The pangenome analysis on the 17 R. gnavus reference
genomes confirmed the presence of two distinct clades
as identified by their SNP profiles (Additional file 6:
Figure S1). Two previously reported R. gnavus reference
genomes were present in clade 2, but neither were from
healthy adults (Additional file 5: Table S5). Using all
metagenomic samples from the LSS, Lewis et al., and
HMP cohorts, we found that R. gnavus strains from all
controls and some IBD patients belonged to clade 1. On
the other hand, only R. gnavus strains from IBD patients
belonged to clade 2. Importantly, strains from clade 2
were present in patients originating from three different
clinical centers in the US, suggesting the generality of
this observation. The functional characterization of both
Fig. 3 R. gnavus metagenomic strain phylogeny. A phylogenetic tree of R. gnavus strains, calculated from SNP profiles of R. gnavus marker genes
(see “Methods”), where each tree leaf is a sample from the LSS or Lewis et al. cohorts (subject plus time point). Subject SKST012 is the only included
control individual, as no other control metagenomes contained enough R. gnavus reads for detection and strain assignment by StrainPhlAn. Bootstrap
values are indicated on branches and reveal two distinct clades of R. gnavus strains
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clades highlighted three more cases of blooms of R.
gnavus clade 2 (patients 9216, 8712, and 9193). Interest-
ingly, R. gnavus clade 2 was also identified in infants from
the DIABIMMUNE cohort (RJX1118 and RJX1119;
Additional file 6: Figure S1) [10] where the abundance
of R. gnavus is considerably higher than in healthy adults.
Using 80 healthy controls from the HMP, no individuals
with R. gnavus clade 2 were identified. Taken together, we
concluded that R. gnavus clade 2 was enriched in strains
from adults with IBD.
R. gnavus clade 2 strains harbor IBD-specific genes
To understand the functional potential of each clade, we
searched for individual R. gnavus genes that were not
detected in any healthy individuals and present in at
least two IBD samples with greater than 10× cumulative
coverage. We identified 199 such IBD-specific genes
(Fig. 4). These genes are involved in various functions
that may improve colonization of the IBD gut, including
oxidative stress responses, adhesion, iron acquisition,
and mucus utilization, as well as a range of other general
functions (Additional file 7: Table S6).
Three IBD-specific gene families are likely involved in
the response to oxidative stress. Two IBD-specific genes
encode peroxiredoxin and NADH oxidase, proteins that
may act as a potent peroxidase, which could provide
extra protection against oxidative stress in the IBD gut
[22]. Another IBD-specific gene product, cystathionine
gamma-lyase, is involved in the biosynthesis of cysteine,
which is necessary for the biosynthesis of glutathione, an
important antioxidant [23]. These results indicate that
R. gnavus clade 2 strains may be specifically adapted to
tolerate the higher oxidative stress of the IBD gut.
Three additional IBD-specific gene families are involved
in the acquisition of iron. Iron is an essential nutrient
for almost all bacteria, and is often a limiting nutrient.
Fig. 4 Functional profiles of IBD-related R. gnavus strains; 199 IBD-specific genes within R. gnavus (rows) and their depth of coverage across metagenomic
samples (columns). All samples with at least 1× coverage of the R. gnavus pangenome are shown. Cluster of genes indicate that different strain groups
(clades; Fig. 3) have different subsets of IBD-specific genes. Several gene families of interest are highlighted (see text), and the full R. gnavus pangenome
can be found in Additional file 5: Figure S1
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Additional genes involved in iron acquisition could be
adaptive for colonization of the IBD gut because anemia is
common in patients with IBD [24]. Two of these gene
families were annotated as iron ABC transporters and
the third as an enterochelin esterase, which makes iron
chelated by siderophores available for use.
Previous studies have reported that some strains of
R. gnavus utilize mucosal glycans. We found an IBD-
specific gene involved in sialic acid transport, which may
improve the efficiency of mucus utilization [25]. Thirteen
IBD-specific gene families are involved in sugar utilization,
including glycoside hydrolases and sugar transporters,
which may allow for utilization of an expanded repertoire
of sugars as carbon sources (Additional file 8: Table S7).
Finally, one IBD-specific gene is annotated as a lanti-
peptide synthetase which is involved in the biosynthesis
of modified peptides, many of which have antimicrobial
effects. Some strains of R. gnavus are known to produce
the lantipeptide ruminococcin A, which inhibits the
colonization of Clostridium species [26]. Lantipeptides
could thus provide R. gnavus a competitive advantage
in colonizing the gut.
The IBD-specific genes are likely evidence for collective
adaption to the IBD gut by R. gnavus strains. The fact that
nine of the genes are associated with mobile elements
such as transposase, phage tail tape measure, or relaxo-
some proteins indicates that many of these genes were
likely “cargo genes” of mobile genetic elements acquired
by R. gnavus (Additional file 8: Table S7). Thus, the IBD-
specific genes are not “core” genes for clade 2, but likely
have been acquired and retained because they collectively
provide an adaptive advantage in the microenvironment
of the IBD gut.
Discussion
The results presented here are concordant with the
hypothesis that a major feature of the dysbiosis of the
gut microbiome in IBD is a shift towards organisms that
can cope with increased oxidative stress [27]. Import-
antly, resistance to oxidative stress is widely, yet sparsely,
distributed throughout the gut microbiome phylogeny. It
is thus not well addressed by simple taxonomic binning.
The microbial shift towards facultative anaerobes has
several important implications for the pathophysiology
of IBD. We found that the strongest, yet transient, devi-
ation in the microbial composition of IBD patients was
the bloom of R. gnavus from an average of 0.1% in our con-
trols to up to 69% in IBD patients with active disease. The
physiologic niche of R. gnavus is likely mucolytic (utilizing
glycans from the intestinal mucus layer as energy sources).
We speculate that the dramatic change in R. gnavus abun-
dance affects the delicate equilibrium of the mucus layer,
due to the dramatic increase in the fraction of the commu-
nity utilizing the mucus layer. This disequilibrium could in
turn influence the gut barrier integrity, potentially increas-
ing the intestinal permeability of IBD patients.
Whether the increased abundance of R. gnavus in IBD is
a cause or effect of inflammation is currently unknown. At
the very least, R. gnavus is a superlative colonizer of the
inflamed IBD gut. However, it is also possible that R.
gnavus contributes to or exacerbates the excessive im-
mune response to the gut microbiome in IBD patients. In
addition to its increased abundance in IBD, other studies
have implicated R. gnavus as a potential pathobiont. Three
cases of R. gnavus bacteremia and a case of infection of the
bone surrounding a hip implant by R. gnavus have been
reported [28–30]. In a study about treating UC patients
with fecal microbiome transplants, patients who received
stool from donors with high R. gnavus were more likely to
relapse [31], suggesting a causal role in disease. Denser
sampling of patients prior to flares, during their treatment,
and after remission will enable the field to further examine
the role of R. gnavus in IBD disease activity.
The original misclassification of R. gnavus, combined
with 16S amplicon sequencing limitations for species-level
identification, have confounded analysis in previous IBD
studies, and left the significance of R. gnavus in the
dysbiosis of IBD underappreciated. R. gnavus, a member
of the phylum Firmicutes, is present in the gut of ~ 90%
individuals (though at low abundance). Yet its genus clas-
sification has been recently disputed. Originally classified
as a member of the Ruminococcus genus by Moore et al.
[21], it has been recently transferred to the Blautia genus
based on 16S rRNA gene sequencing [32, 33]. Specifically,
true Ruminococcus species have decreased abundance
in IBD patients, masking the increased abundance of R.
gnavus in these samples, when examined only at the
genus level.
Conclusions
One major advantage of this study is that the coupling of
longitudinal samples with whole metagenome sequencing
has allowed us to study the IBD gut microbiome at the
unprecedented resolution of strains and their functional
potential. The accurate species- and strain-level identi-
fication afforded by whole metagenome sequencing is
especially critical in understanding the abundance of R.
gnavus, as 16S rRNA gene sequences from Blautia species
are highly similar and most 16S analysis has therefore
summarized at genus Blautia. Specifically, in IBD, the
abundance of different Blautia species change in the
opposite direction, completely masking R. gnavus blooms.
We used the metagenomic sequencing to go beyond taxo-
nomic profiling and study the functional differences among
various R. gnavus strains. Taken together, our results reveal
a clade of R. gnavus strains that may be better adapted to
the IBD gut, through mechanisms of oxidative stress re-
sponses, adhesion, iron acquisition, and mucus utilization.
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